z-logo
Premium
Single pass tangential flow filtration to debottleneck downstream processing for therapeutic antibody production
Author(s) -
DizonMaspat Jemelle,
Bourret Justin,
D'Agostini Anna,
Li Feng
Publication year - 2012
Publication title -
biotechnology and bioengineering
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.136
H-Index - 189
eISSN - 1097-0290
pISSN - 0006-3592
DOI - 10.1002/bit.24377
Subject(s) - bottleneck , process engineering , downstream processing , filtration (mathematics) , cross flow filtration , downstream (manufacturing) , process (computing) , biochemical engineering , limiting , continuous production , production (economics) , upstream (networking) , computer science , environmental science , chromatography , chemistry , engineering , mathematics , mechanical engineering , environmental engineering , operating system , computer network , biochemistry , statistics , operations management , membrane , economics , macroeconomics , embedded system
Abstract As the therapeutic monoclonal antibody (mAb) market continues to grow, optimizing production processes is becoming more critical in improving efficiencies and reducing cost‐of‐goods in large‐scale production. With the recent trends of increasing cell culture titers from upstream process improvements, downstream capacity has become the bottleneck in many existing manufacturing facilities. Single Pass Tangential Flow Filtration (SPTFF) is an emerging technology, which is potentially useful in debottlenecking downstream capacity, especially when the pool tank size is a limiting factor. It can be integrated as part of an existing purification process, after a column chromatography step or a filtration step, without introducing a new unit operation. In this study, SPTFF technology was systematically evaluated for reducing process intermediate volumes from 2× to 10× with multiple mAbs and the impact of SPTFF on product quality, and process yield was analyzed. Finally, the potential fit into the typical 3‐column industry platform antibody purification process and its implementation in a commercial scale manufacturing facility were also evaluated. Our data indicate that using SPTFF to concentrate protein pools is a simple, flexible, and robust operation, which can be implemented at various scales to improve antibody purification process capacity. Biotechnol. Bioeng. 2012; 109:962–970. © 2011 Wiley Periodicals, Inc.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here